Previous 10 | Next 10 |
home / stock / mvrbf / mvrbf news
Medivir AB press release (OTC:MVRBF): Q1 GAAP EPS of -SEK 0.59. Revenue of SEK 0.5M (-94.9% Y/Y). For further details see: Medivir AB GAAP EPS of -SEK 0.59, revenue of SEK 0.5M
Medivir AB press release (OTC:MVRBF): FY GAAP EPS of -SEK 0.44. Revenue of SEK 13.9M (+826.7% Y/Y). Outlook: Medivir’s future investments will mainly be in clinical pharmaceutical projects within oncology. It is the view from Board of Directors and management that the current cash...
Birinapant clinical study initiated by IGM Biosciences PR Newswire STOCKHOLM , Nov. 4, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR ) today announced that IGM Biosciences, Inc. has initiated its clinical study in solid cancers with birinapant (...
Medivir to present at the ProHearings shared Capital Markets Day PR Newswire STOCKHOLM , Oct. 11, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the ProHearings shared Capital Markets Day, Octo...
Medivir AB ([[MVRBF]]) announces that it has appointed Malene Jensen as Vice President Clinical Development.Jensen has held various leadership positions within Clinical Development in the pharmaceutical industry for the past 15 years, including at AstraZeneca, Affibody and most...
Medivir appoints Malene Jensen as VP Clinical Development PR Newswire STOCKHOLM , July 1, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Malene Jensen as Vice President Clinical Development. She will assume her r...
Medivir to present at the Redeye Growth Day PR Newswire STOCKHLOM, June 1, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the virtual meeting Redeye Growth Day on June 2, 2021 . The presenta...
Medivir to present at the ABGSC Life Science Summit PR Newswire STOCKHOLM , May 25, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will present at the virtual meeting ABGSC Life Science Summit, today, May 25 . The ...
Medivir AB ([[MVRBF]]) announces positive results from the investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma ((SCC)).The primary objective of the study was to assess the effects of topical remetinostat on biopsy-proven SCC and SCC in ...
Medivir AB (MVRBF) has appointed Magnus Christensen, the company's CFO, as interim CEO.Magnus has been CFO of the company since 2019 and in parallel will retain his role as CFO. Magnus succeeds Yilmaz Mahshid.The board has initiated the recruitment process for a new CEO. For further de...
News, Short Squeeze, Breakout and More Instantly...
Medivir B Company Name:
MVRBF Stock Symbol:
OTCMKTS Market:
MEDIVIR AB - INTERIM REPORT JANUARY - JUNE 2022 PR Newswire STOCKHOLM , Aug. 19, 2022 /PRNewswire/ -- The clinical development of fostrox remains the focus April - June Financial summary for the quarter Net turnover amoun...
Birinapant clinical study initiated by IGM Biosciences PR Newswire STOCKHOLM , Nov. 4, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR ) today announced that IGM Biosciences, Inc. has initiated its clinical study in solid cancers with birinapant (...
Medivir to present at the ProHearings shared Capital Markets Day PR Newswire STOCKHOLM , Oct. 11, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the ProHearings shared Capital Markets Day, Octo...